QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.133751v1 325/2/484    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reddy, L. H. Articles by Couvreur, P. Search for Related Content PubMed PubMed Citation Articles by Reddy, L. H. Articles by Couvreur, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cancer Chemotherapy Hazardous Substances DB CYTARABINE

TOXICOLOGY

Preclinical Toxicology (Subacute and Acute) and Efficacy of a New Squalenoyl Gemcitabine Anticancer Nanomedicine

Université Paris-Sud XI, Faculté de Pharmacie, Unité Mixte de Recherche Centre National de la Recherche Scientifique 8612, Institut Fédératif de Recherche 141, Châtenay-Malabry Cedex, France (L.H.R., C.D., P.C.); Medsqual, Paris Biotech, Paris, France (P.-E.M.); and Université Paris-Sud XI, Faculté de Pharmacie, Unité Mixte de Recherche Centre National de la Recherche Scientifique 8076 Biocis, Châtenay-Malabry Cedex, France (S.-L.M., D.D.)

This study investigates 1) the anticancer efficacy of a new squalenoyl prodrug of gemcitabine (SQgem) in nanoassembly form compared with gemcitabine at equitoxic doses and 2) the subacute and acute preclinical toxicity of these compounds. The toxicity studies revealed that SQgem nanoassemblies, like gemcitabine, were toxic, and they led to dose-dependent mortality after daily i.v. injections for 1 week, irrespective of the route of administration. However, a 4- to 5-day spaced dosing schedule (injections on day 0, 4, 8, and 13) was proved to be safer in terms of weight loss and hematological and other toxicity. Using this spaced dosing schedule, SQgem nanoassemblies exhibited impressive anticancer activity in mice bearing L1210 leukemia because this treatment led to 75% long-term survivors. In contrast, at equitoxic doses, neither free gemcitabine nor cytarabine led to longterm survivors and all the mice of these groups died of the disease. Further toxicity studies performed at lethal doses by blood and serum analysis and organ weight determinations revealed that the hematological toxicity was the dose-limiting toxicity in both SQgem nanoassemblies and gemcitabine, whereas probable gastrointestinal toxicity was also associated with free gemcitabine. The SQgem nanoassemblies did not display hepatotoxicity, which is one of the clinically encountered toxicities of gemcitabine. To summarize, these preclinical studies demonstrated that the toxicological profile of new squalenoyl gemcitabine nanomedicine was not distinct from that of the parent gemcitabine, whereas it was much more potent than gemcitabine at equitoxic doses and cytarabine at clinically relevant doses. These data support the candidature of SQgem for clinical trials.

Address correspondence to: Dr. Patrick Couvreur, Université Paris-Sud XI, Faculté de Pharmacie, Unité Mixte de Recherche Centre National de la Recherche Scientifique 8612, Institut Fédératif de Recherche 141, 92296 Châtenay-Malabry Cedex, France. E-mail: patrick.couvreur{at}u-psud.fr

This article has been cited by other articles:

				L. H. Reddy, H. Khoury, A. Paci, A. Deroussent, H. Ferreira, C. Dubernet, X. Decleves, M. Besnard, H. Chacun, S. Lepetre-Mouelhi, et al. Squalenoylation Favorably Modifies the in Vivo Pharmacokinetics and Biodistribution of Gemcitabine in Mice Drug Metab. Dispos., August 1, 2008; 36(8): 1570 - 1577. [Abstract] [Full Text] [PDF]